A Phase II, Multicentre Booster Study to Evaluate Booster Vaccination With GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or to Evaluate the Immune Memory Following the Administration of a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children, Previously Vaccinated in Infancy in the Primary Study 11PN-PD-DIT-002 (103488)
Latest Information Update: 24 Sep 2023
At a glance
- Drugs Pneumococcal 11-valent vaccine conjugate (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 13 Apr 2012 Planned patient number for the booster trial (EudraCT2008-002345-23) is now 689.
- 13 Apr 2012 Status of the booster trial (NCT00307567) is completed.
- 13 Apr 2012 Actual initiation date for the booster trial (NCT00307567) is now Nov 2005.